<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04915989</url>
  </required_header>
  <id_info>
    <org_study_id>GX-19N-HV-003</org_study_id>
    <nct_id>NCT04915989</nct_id>
  </id_info>
  <brief_title>Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals</brief_title>
  <official_title>A Phase 1, Multicenter, Open-Label, Single Arm Study to Investigate the Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of our study is to demonstrate safety and immunogenicity of COVID-19 preventive&#xD;
      DNA vaccine in elderly individuals.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This clinical study is a phase 1 clinical trial to investigate the safety and immunogenicity&#xD;
      of COVID-19 preventive vaccine by intramuscularly administration in the elderly.&#xD;
&#xD;
      This study is designed as single arm, open-labeled and a total of 30 subjects will be&#xD;
      enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">February 16, 2021</start_date>
  <completion_date type="Anticipated">March 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Solicited Adverse Events</measure>
    <time_frame>Through 1 year post vaccination</time_frame>
    <description>solicited local and systemic AEs after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Unsolicited Adverse Events</measure>
    <time_frame>Through 1 year post vaccination</time_frame>
    <description>unsolicited AEs after vaccination</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious Adverse Events</measure>
    <time_frame>Through 1 year post vaccination</time_frame>
    <description>percentage of subjects with SAEs</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>GMT of Antigen-specific Binding Antibody Titers</measure>
    <time_frame>Through 12 weeks after vaccination</time_frame>
    <description>Geometric mean titer (GMT) of antigen-specific binding antibody after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of Antigen-specific Binding Antibody Titers</measure>
    <time_frame>Through 12 weeks after vaccination</time_frame>
    <description>Geometric mean fold rise (GMFR) of antigen-specific binding antibody after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Who Seroconverted After Vaccination</measure>
    <time_frame>Through 12 weeks after vaccination</time_frame>
    <description>Seroconversion defines as 4-fold increase in antibody titer after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMT of Neutralizing Antibody Level</measure>
    <time_frame>Through 12 weeks after vaccination</time_frame>
    <description>Geometric mean titer (GMT) of neutralizing antibody after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of Neutralizing Antibody Level</measure>
    <time_frame>Through 12 weeks after vaccination</time_frame>
    <description>Geometric mean fold rise (GMFR) of neutralizing antibody after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMSN of Spot Forming Unit (SFU) detected by IFN-gamma ELISPOT assay</measure>
    <time_frame>Through 12 weeks after vaccination</time_frame>
    <description>Geometric mean spot numbers (GMSN) of SFU after vaccination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GMFR of Spot Forming Unit (SFU) detected by IFN-gamma ELISPOT assay</measure>
    <time_frame>Through 12 weeks after vaccination</time_frame>
    <description>Geometric mean fold rise (GMFR) of SFU after vaccination</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Change From Baseline in Antigen-specific IFN-gamma Cellular Immune Response by Immunophenotyping assay</measure>
    <time_frame>Through 12 weeks after vaccination</time_frame>
    <description>Antigen-specific IFN-γ T cell immune response assessed by immunophenotyping assay after vaccination</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>SARS-CoV-2</condition>
  <arm_group>
    <arm_group_label>GX-19N</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dose A of GX-19N will be intramusculary administered via EP on day 1 and day 29. (Optional administration on day 57)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-19N</intervention_name>
    <description>DNA vaccine expressing SARS-CoV-2 S-protein antigen including the Nucleocapsid protein (NP) antigen</description>
    <arm_group_label>GX-19N</arm_group_label>
    <other_name>Dose A</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Able and willing to comply with all study procedures and voluntarily signs informed&#xD;
             consent form&#xD;
&#xD;
          -  Male or female aged 55-85 years&#xD;
&#xD;
          -  Willing to provide specimens such as blood and urine during the study, including end&#xD;
             of study visit.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Immunosuppresion including immunodeficiency disease or family history Any history of&#xD;
             malignant disease within the past 5 years&#xD;
&#xD;
          -  Scheduled to undergo any surgery or dental treatment during the study&#xD;
&#xD;
          -  Having received immunoglobulin or blood-derived drugs or being expected to be&#xD;
             administered within 3 months prior to administration.&#xD;
&#xD;
          -  Having relied on antipsychotic drugs and narcotic analgesics within 6 months before&#xD;
             administration&#xD;
&#xD;
          -  Positive of serology test at screening&#xD;
&#xD;
          -  Suspected of drug abuse or a history within 12 months prior to administration&#xD;
&#xD;
          -  Active alcohol use or history of alcohol abuse&#xD;
&#xD;
          -  Serious adverse reaction to a drug containing GX-19N or other ingredients of the same&#xD;
             categories or to a vaccine or antibiotic, nonsteroidal anti-inflammatory disease&#xD;
             control, etc. or an allergic history&#xD;
&#xD;
          -  History of hypersensitivity to vaccination such as Guillain-Barre syndrome&#xD;
&#xD;
          -  Those with significant chronic underlying diseases that may increase the risk of&#xD;
             COVID-19 or interfere with the evaluation of clinical trial purposes according to the&#xD;
             investigator's discretion&#xD;
&#xD;
          -  Having hemophilia at risk of causing serious bleeding when injected intramuscularly or&#xD;
             receiving anticoagulants&#xD;
&#xD;
          -  Subjects who have been contact with COVID-19 infections in the past prior to&#xD;
             administration, have been classified as COVID-19 confirmed patients, medical patients&#xD;
             or patients with symptoms or have been identified with SARS and MERS infection history&#xD;
             in the past&#xD;
&#xD;
          -  Acute fever, cough, difficulty breathing, chills, muscle aches, headache, sore throat,&#xD;
             loss of smell, or loss of taste within 72 hours prior to administration&#xD;
&#xD;
          -  Other vaccination history within 28 days prior to the administration or being&#xD;
             scheduled to be inoculated during the study&#xD;
&#xD;
          -  History of having taken immunosuppressant or Immune modifying drug within 3 months&#xD;
             prior to administration&#xD;
&#xD;
          -  Having participated and had clinical trial drug administration in another clinical&#xD;
             trial or biological equivalence study within 6 months prior to the administration&#xD;
&#xD;
          -  Pregnant or breastfeeding female, however, those are allowed to participate in the&#xD;
             study only if they stop breastfeeding before participation (fertile female† must be&#xD;
             negative in serum pregnancy test at screening&#xD;
&#xD;
          -  Fertile female who do not agree to use effective contraception methods (condoms,&#xD;
             contraceptive diaphragm, intrauterine contraceptive devices) during the study&#xD;
&#xD;
          -  Any other clinically significant medical or psychiatric finding which is considered&#xD;
             inappropriate by investigator&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jun Yong Choi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Severance Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Severance hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangnam Severance hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06273</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>June 3, 2021</study_first_submitted>
  <study_first_submitted_qc>June 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2021</study_first_posted>
  <last_update_submitted>June 4, 2021</last_update_submitted>
  <last_update_submitted_qc>June 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

